Avicella Capital

Avicella Capital is a venture capital firm funding early-stage healthcare assets to improve patient outcomes, quality, and human longevity. The firm invests across therapeutics, medical devices, diagnostics, and health technology. They prioritize assets with established proof-of-concept and clear mechanisms, focusing on solutions that expedite recovery, enhance diagnostic precision, or optimize operations using data and AI.

Co-founded in 2024 by Dr. Gennady Bratslavsky, Brooke Raphael, and David Saab, Avicella Capital provides specialized capital to early-stage life science ventures. Dr. Bratslavsky, a prominent medical expert, contributes clinical and scientific depth. The founders' insight: targeted investment and deep industry expertise accelerate medical innovations from development to impactful patient applications.

The firm partners with companies developing cutting-edge medical technologies and therapies, from novel drug candidates to advanced diagnostic platforms. Avicella Capital’s mission is to revolutionize healthcare by backing developments that reduce morbidity and enhance global quality of life. Their long-term vision centers on extending human lifespan through strategic investments in transformative life science companies.